-- SB1 Markets on Tuesday initiated coverage of Danish drugmaker Novo Nordisk (NOVO-B.CO) with a buy rating and a price target of 280.00 Danish kroner.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)